Horizon Technology Finance Corporation (HRZN) provides venture lending and growth-capital financing to development-stage and growth companies in technology, life science, healthcare information and services, and sustainability. Its recurring announcements address secured loan facilities, portfolio activity, net investment income and NAV, monthly cash distributions and special distributions, and capital allocation by its board.
Company updates also cover its external management by Horizon Technology Finance Management LLC, affiliation with Monroe Capital, the completed merger with Monroe Capital Corporation, and the HRZN CRFH LLC joint venture focused on growth financing for small- and micro-cap public companies.
Horizon Technology Finance (NASDAQ: HRZN) provided a $40 million loan facility to Hyperfine (NASDAQ: HYPR), with $15 million funded at closing and up to $25 million available to support future commercial growth. The financing targets expansion of Hyperfine's FDA-cleared Swoop® point-of-care MR brain imaging system across hospitals and offices.
The facility is presented as supporting Hyperfine's commercial scale-up, a second-generation device rollout, and broader adoption of portable neuroimaging in acute and chronic care settings.
Horizon Technology Finance (NASDAQ: HRZN) and CR Financial Holdings formed a $100 million joint venture to provide growth capital financing to U.S.-based small- and micro-cap public companies.
The JV will target secured loans in the $5–25 million range, use warehouse credit facilities to leverage capital, and be governed by equal representation on a four-person board and investment committee. The venture expects support from Monroe Capital, which had approximately $24 billion AUM as of January 1, 2026.
Horizon Technology Finance (NASDAQ: HRZN) announced the HRZN Board intends to use $27.6 million of undistributed taxable earnings as of December 31, 2025 to supplement regular monthly distributions to combined-company stockholders for two quarters after the closing of the pending merger with Monroe Capital Corporation.
The Board anticipates supplemental distributions for the first post-close quarter of at least $0.02 to $0.04 per share per month, subject to closing, Board declaration, asset coverage, financing covenants, liquidity and market conditions. MRCC separately intends a $13.0 million supplemental pre-merger distribution (about $0.61 per share), contingent on stockholder approval and closing conditions. HRZN’s special meeting is scheduled for March 13, 2026.
Horizon Technology Finance (NASDAQ: HRZN) declared monthly cash distributions of $0.06 per share payable in April, May and June 2026, totaling $0.18 per share. Payments have ex-dividend/record and payment dates in March–May 2026, with payments in April–June 2026.
The Board bases distributions on results, spillover income and outlook, and notes taxable income for distributions will be finalized after year-end. Horizon offers a Dividend Reinvestment Plan (DRIP) and may satisfy DRIP shares via new-issue or open-market purchases.
Horizon Technology Finance (NASDAQ: HRZN) reported Q4 2025 net investment income (NII) of $8.3M ($0.18/share) and NAV of $318.5M ($6.98/share) as of December 31, 2025. Annualized debt portfolio yield was 14.3% for Q4 and 15.8% for full-year 2025.
The Company ended 2025 with a total portfolio of $647.2M, committed backlog of $154M, cash of $142.7M, credit facility capacity of $329.0M, and undistributed spillover income of $0.65/share. The Board declared monthly distributions of $0.06/share for April–June 2026 and continues progress toward the anticipated merger with MRCC.
Horizon Technology Finance (NASDAQ: HRZN) will release fourth-quarter 2025 financial results for the period ended December 31, 2025 on March 3, 2026 after market close. A conference call to discuss results is scheduled for March 4, 2026 at 9:00 a.m. ET.
Executives participating include Mike Balkin (CEO), Paul Seitz (SVP & CIO), and Dan Trolio (EVP & CFO). The call is accessible by phone and via a live listen-only webcast on the company website; an online archive will be available for 30 days.
Horizon Technology Finance (NASDAQ: HRZN) and Monroe Capital closed an initial $40 million senior credit facility for Ossio Inc., with an additional $10 million available to support future growth. The financing aims to accelerate OSSIO’s global expansion of its metal-free OSSIOfiber bone regeneration technology, with development and manufacturing in Caesarea, Israel, and commercial operations in Palmetto, FL.
This growth capital positions OSSIO to scale commercialization while Horizon and Monroe provide strategic healthcare and Israeli technology ecosystem expertise.
Summary not available.
Horizon Technology Finance (Nasdaq: HRZN) priced a registered direct offering of $57.50 million aggregate principal amount of 7.00% Notes due December 15, 2028. Interest is 7.00% annually, payable June 15 and December 15, beginning December 15, 2025. The Notes may be redeemed prior to June 15, 2028 at par plus a make-whole premium and thereafter at par plus accrued interest.
The company expects delivery on or about December 15, 2025, with Oppenheimer & Co. as sole book-running manager. The company intends to use net proceeds to repay indebtedness, including its 4.875% Notes due 2026, and for general corporate purposes. The Notes are not expected to be listed.
Horizon Technology Finance (NASDAQ: HRZN) declared monthly cash distributions of $0.11 per share payable on January 15, 2026, February 13, 2026, and March 13, 2026, totaling $0.33 per share for the first quarter of 2026.
The Board based the declaration on third quarter operating results and spillover income, and said it will reassess distributions in February 2026 after fourth quarter 2025 results and spillover at December 31, 2025, taking into account the anticipated merger with Monroe Capital. Since its 2010 IPO, Horizon has paid $340 million in distributions. Horizon offers a Dividend Reinvestment Plan that may issue new shares or use open-market purchases to satisfy reinvestment.